Sophia Genetics has developed a new artificial intelligence clinical application for clinicians to use when analyzing liquid biopsy results. The new application utilizes the AI analytical platform SOPHiA to help clinicians diagnose cancer early by offering a standardized approach to DNA analysis in liquid biopsy testing; this approach was built on data mined from the network of hospitals already using Sophia Genetics' AI technology for genomic data analysis.
SOPHiA analyzes circulating tumor DNA (ctDNA), contained in patients’ liquid samples such as blood, urine, and cerebral spinal fluid and is currently used by 305 hospitals in over 50 countries